Melissa Mannion

Dr. Melissa Mannion

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2022 in Arthritis & Rheumatology
Verified
Journal Article
Closed access
KOKaren B. Onel
Karen B. Onel
DHDaniel B Horton
Daniel B Horton
DLDaniel Joe Lovell
Daniel Joe Lovell
SSSusan Shenoi
Susan Shenoi
CCCarlos A. Cuello
Carlos A. Cuello
JRJames T. Reston
James T. Reston

1 March 2022 in Arthritis Care & Research
Verified
Journal Article
Closed access
KOKaren B. Onel
Karen B. Onel
DHDaniel B Horton
Daniel B Horton
DLDaniel Joe Lovell
Daniel Joe Lovell
SSSusan Shenoi
Susan Shenoi
CCCarlos A. Cuello
Carlos A. Cuello
JRJames T. Reston
James T. Reston

4 January 2011 in Pediatric Rheumatology
Verified
Journal Article
Open access
PDF file
MMMelissa Mannion
Melissa Mannion
RCRandy Q. Cron
Randy Q. Cron
Autoimmune pancreatitis is frequently associated with elevated serum and tissue IgG4 levels in the adult population, but there are few reports of pediatric autoimmune pancreatitis, and even fewer reports of IgG4 related systemic disease in a pediatric population. The standard of care treatment in adults is systemic corticosteroids with resolution of symptoms in most cases; however, multiple courses of corticosteroids are occasionally required and some patients require long term corticosteroids. In these instances, steroid sparing disease modify treatments are in demand. We describe a 13-year-old girl with IgG4 related systemic disease who presented with chronic recurrent autoimmune pancreatitis resulting in surgical intervention for obstructive hyperbilirubinemia and chronic corticosteroid treatment. In addition, she developed fibrosing medianstinitis as part of her IgG4 related systemic disease. She was eventually successfully treated with mycophenolate mofetil allowing for discontinuation of corticosteroids. This is the first reported use of mycophenolate mofetil for IgG4 related pancreatitis. Although autoimmune pancreatitis as part of IgG4 related systemic disease is rarely reported in pediatrics, autoimmune pancreatitis is also characterized as idiopathic fibrosing pancreatitis. All pediatric autoimmune pancreatitis cases reported in the world medical literature were identified via a PUBMED search and are reviewed herein. Twelve reports of pediatric autoimmune pancreatitis were identified, most of which were treated with corticosteroids or surgical approaches. Most case reports failed to report IgG4 levels, so it remains unclear how commonly IgG4 related autoimmune pancreatitis occurs during childhood. Increased evaluation of IgG4 levels in patients with autoimmune pancreatitis may shed further light on the association of IgG4 with pancreatitis and the underlying pathophysiology.

1 March 2022 in Arthritis Care & Research
Verified
Journal Article
Closed access
KOKaren B. Onel
Karen B. Onel
DHDaniel B Horton
Daniel B Horton
DLDaniel Joe Lovell
Daniel Joe Lovell
SSSusan Shenoi
Susan Shenoi
CCCarlos A. Cuello
Carlos A. Cuello
JRJames T. Reston
James T. Reston

15 February 2019 in The Journal of Rheumatology
Verified
Journal Article
Closed access
PDF file
EMEsi M. Morgan
Esi M. Morgan
JMJane E. Munro
Jane E. Munro
JHJennifer Horonjeff
Jennifer Horonjeff
BHBen Horgan
Ben Horgan
BSBeverley Shea
Beverley Shea
ACAlessandro Consolaro
Alessandro Consolaro
Objective.: The current Juvenile Idiopathic Arthritis (JIA) Core Set used in randomized controlled trials (RCT) and longitudinal observational studies (LOS) was developed without the input of patients/parents. At the Outcome Measures in Rheumatology (OMERACT) 2016, a special interest group voted to reconsider the core set, incorporating broader input. We describe subsequent work culminating in an OMERACT 2018 plenary and consensus voting.Methods.: Candidate domains were identified through literature review, qualitative surveys, and online discussion boards (ODB) held with patients with JIA and parents in Australia, Italy, and the United States. A Delphi process with parents, patients, healthcare providers, researchers, and regulators served to edit the domain list and prioritize candidate domains. After the presentation of results, OMERACT workshop participants voted, with consensus set at > 70%.Results.: Participants in ODB were 53 patients with JIA (ages 15–24 yrs) and 55 parents. Three rounds of Delphi considering 27 domains were completed by 190 (response rate 85%), 201 (84%), and 182 (77%) people, respectively, from 50 countries. There was discordance noted between domains prioritized by patients/parents compared to others. OMERACT conference voting approved domains for JIA RCT and LOS with 83% endorsement. Mandatory domains are pain, joint inflammatory signs, activity limitation/physical function, patient’s perception of disease activity (overall well-being), and adverse events. Mandatory in specific circumstances: inflammation/other features relevant to specific JIA categories.Conclusion.: Following the OMERACT methodology, we developed an updated JIA Core Domain Set. Next steps are to identify and systematically evaluate best outcome measures for these domains.

14 November 2018 in Pediatric Rheumatology
Verified
Journal Article
Open access
PDF file
CCCourtney B. Crayne
Courtney B. Crayne
EEEsraa Eloseily
Esraa Eloseily
MMMelissa Mannion
Melissa Mannion
SASaji P. Azerf
Saji P. Azerf
PWPeter Weiser
Peter Weiser
RCRandy Q. Cron
Randy Q. Cron
Henoch-Schonlein purpura (HSP) is a small vessel vasculitis that is characterized by non-thrombocytopenic purpura, abdominal pain, arthritis, and glomerulonephritis. Typically, HSP is self-limited requiring only supportive care, but more severe cases may require corticosteroid (CS) treatment. Rarely, a subset of these patients has persistent rash, arthritis, abdominal involvement, or renal disease despite treatment with CS, or has disease recurrence on CS tapering. Refractory HSP has been effectively treated with a variety of CS sparing therapies. For life-threatening refractory HSP, the B cell depleting agent, rituximab (RTX), has been reported as beneficial for children with substantial renal or central nervous system involvement. However, RTX use for children with less severe HSP, but chronic CS dependent disease refractory to CS sparing immunomodulatory agents, has been less well explored. Herein, we describe 8 children treated with RTX for chronic refractory HSP and report a reduction in recurrent hospitalizations and eventual CS discontinuation. This is a retrospective analysis of eight children who were treated with RTX for chronic CS dependent HSP during the years 2006–2014 at a single institution. A chart review of the electronic medical record was performed to determine the presenting symptoms, the type and duration of treatment received, and the number of hospitalizations prior to and after RTX. The number of hospitalizations and oral corticosteroid burden were analyzed using the Wilcoxon signed rank test. Prior to receiving RTX, seven patients had at least one hospitalization for HSP (median 1.5, range 0–3). Following RTX, only two patients were hospitalized, each a single time for recurrent abdominal pain. The median oral CS burden was 0.345 mg/kg/day before RTX and 0 mg/kg/day at 6 months (p = 0.078), 1 year (p = 0.0625), and 2 years (p = 0.03) following RTX infusion. Seven out of eight children met remission criteria, defined as no active rash, arthritis, nephritis (hematuria and proteinuria), or gastrointestinal distress following RTX. No serious adverse events were noted. Overall, RTX effectively reduced the number of hospital admissions and oral CS burden. RTX also helped most all children achieve clinical remission. RTX appears to be an effective and safe alternative for chronic CS dependent and immunomodulatory refractory childhood HSP.